• LAST PRICE
    3.3200
  • TODAY'S CHANGE (%)
    Trending Down-0.0600 (-1.7751%)
  • Bid / Lots
    2.9500/ 1
  • Ask / Lots
    3.6000/ 2
  • Open / Previous Close
    3.4300 / 3.3800
  • Day Range
    Low 3.3100
    High 3.6800
  • 52 Week Range
    Low 1.7501
    High 5.2500
  • Volume
    4,453
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.38
TimeVolumeCYCN
10:46 ET2893.41
11:29 ET1503.3489
02:26 ET2003.68
02:36 ET1003.45
02:42 ET2503.52
02:51 ET2163.31
03:03 ET20003.3995
03:07 ET3003.32
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCYCN
Cyclerion Therapeutics Inc
9.0M
-0.8x
---
United StatesGCTK
GlucoTrack Inc
9.1M
-0.9x
---
United StatesADXS
Ayala Pharmaceuticals Inc
9.0M
0.0x
---
United StatesMIRA
Mira Pharmaceuticals Inc
8.7M
-0.7x
---
United StatesBUDZ
Weed Inc
8.6M
-6,980.0x
---
United StatesNLSP
NLS Pharmaceutics AG
9.3M
-0.6x
---
As of 2024-07-13

Company Information

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Contact Information

Headquarters
301 Binney StreetCAMBRIDGE, MA, United States 02142
Phone
617-621-7722
Fax
---

Executives

Independent Chairman of the Board
Errol De Souza
President
Regina Graul
Chief Financial Officer
Rhonda Chicko
Director
Peter Hecht
Independent Director
Michael Higgins

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.0M
Revenue (TTM)
$0.00
Shares Outstanding
2.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.95
EPS
$-4.38
Book Value
$4.56
P/E Ratio
-0.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.